Last updated: 11/03/2018 16:01:07
This product has been transferred to Novartis. GSK Clinical Study Register is no longer maintained for this study. The most up to date information is available on clinicaltrials.gov.
Efficacy and Safety of Pazopanib Monotherapy after First-line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Asian Women
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
No longer a GSK study
No longer a GSK study
Trial overview
Official title: A Study to Evaluate Efficacy and Safety of Pazopanib Monotherapy in Asian women who have not progressed after first-line chemotherapy for advanced ovarian, fallopian tube or primary peritoneal carcinoma – An extension study to VEG110655
Trial description: This is a study to determine whether therapy with pazopanib is effective and safe in Asian women with epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer has not progressed on first-line chemotherapy.
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Allocation:
Randomized
Primary outcomes:
Progression-free survival (PFS)
Timeframe: From randomization until evidence of progressive disease or death, whichever occurred first (average of 15.2 months)
Secondary outcomes:
Overall survival
Timeframe: From randomization until death due to any cause (average of 29.4 months)
PFS by Gynaecologic Cancer Intergroup (GCIG) criteria
Timeframe: From randomization to the earliest date of disease progression per GCIG criteria or death due to any cause (average of 15.2 months)
Number of participants with any dose reduction or any dose interruption
Timeframe: From Week 1 until the end of the treatment period (up to Study Week 108)
Number of participants with any non-serious adverse event (AE) and any serious adverse event (SAE)
Timeframe: From Week 1 until the end of the treatment period (up to Study Week 108)
Number of participants with any on-therapy AE and any AE related to study treatment
Timeframe: From Week 1 until the end of the treatment period (up to Study Week 108)
Number of participants with any Grade 3 or 4 AE
Timeframe: From Week 1 until the end of the treatment period (up to Study Week 108)
Number of participants with the indicated on-therapy Grade 3-5 AEs
Timeframe: From Week 1 until the end of the treatment period (up to Study Week 108)
Number of participants with AEs leading to permanent discontinuation of study treatment, dose interruption, and dose reduction
Timeframe: From Week 1 until the end of the treatment period (up to Study Week 108)
Number of participants with any SAE, any SAE related to study treatment, and any fatal SAE
Timeframe: From Week 1 until the end of the treatment period (up to Study Week 108)
Number of participants with the indicated worst-case on-therapy blood pressure shifts from Baseline
Timeframe: From Week 1 until the end of the treatment period (up to Study Week 108)
Number of participants with the indicated worst-case on-therapy shift from Baseline in Bazett's corrected QT interval (QTc)
Timeframe: From Week 1 until the end of the treatment period (up to Study Week 108)
Number of participants with the indicated worst-case on-therapy hematology parameter grade shifts from Baseline grade
Timeframe: From Week 1 until the end of the treatment period (up to Study Week 108)
Number of participants with the indicated worst-case on-therapy chemistry parameter grade shifts from Baseline grade
Timeframe: From Week 1 until the end of the treatment period (up to Study Week 108)
Number of participants with the indicated worst-case Eastern Cooperative Oncology Group (ECOG) performance status shifts from Baseline grades of 0, 1, and 2
Timeframe: From Week 1 until the end of the treatment period (up to Study Week 108)
Interventions:
Drug: Pazopanib
Drug: Placebo comparator
Enrollment:
145
Observational study model:
Not applicable
Primary completion date:
2012-12-10
Time perspective:
Not applicable
Clinical publications:
Not applicable
Medical condition
Neoplasms, Ovarian
Product
pazopanib
Collaborators
Not applicable
Study date(s)
September 2010 to January 2014
Type
Interventional
Phase
2
Participation criteria
Sex
Female
Age
18+ years
Accepts healthy volunteers
No
- written informed consent
- At least 18 years old.
- Either (a) bulky disease, or (b) any residual disease which in the opinion of the investigator will need imminent second-line therapy
- Synchronous primary endometrial carcinoma, or a past history of primary endometrial carcinoma, are excluded unless certain conditions are met.
Inclusion and exclusion criteria
Inclusion criteria:
- written informed consent
- At least 18 years old.
- Histologically confirmed, International Federation of Gynecology and Obstetrics (FIGO) stage II-IV epithelial ovarian, fallopian tube or primary peritoneal carcinoma that was treated with surgical debulking and at least five cycles of platinum-taxane doublet chemotherapy.
- Study randomization at least 3 weeks and not more than 12 weeks from the date of the last chemotherapy dose, and all major toxicities from the previous chemotherapy must have resolved.
- No evidence of disease progression
- Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to 2
- Able to swallow and retain oral medication.
- Adequate hematologic, hepatic, and renal system function as follows: Hematologic
- Absolute neutrophil count (ANC) at least 1.5 X 10^9/L
- Hemoglobin at least 9 g/dL (or 5.59 mmol/L)
- Platelets at least 100 X 10^9/L
- Prothrombin time (PT) or international normalized ratio (INR) up to 1.2 X ULN
- Activated partial thromboplastin time (aPTT) up to 1.2 X ULN Hepatic
- Total bilirubin up to 1.5 X ULN
- AST and ALT up to 2.5 X ULN Renal
- Serum creatinine up to 1.5 mg/dL Or, if greater than 1.5 mg/dL: Calculated creatinine clearance at least 50 mL/min Urine Protein
- Urine protein is 0, trace, or +1 determined by dipstick urinalysis, or < 1.0 gram determined by 24-hour urine protein analysis.
- Non-childbearing potential (i.e., physiologically incapable of becoming pregnant) OR childbearing potential, and agrees to use adequate contraception.
Exclusion criteria:
- Either (a) bulky disease, or (b) any residual disease which in the opinion of the investigator will need imminent second-line therapy
- Synchronous primary endometrial carcinoma, or a past history of primary endometrial carcinoma, are excluded unless certain conditions are met.
- Clinically significant gastrointestinal abnormalities
- Prolongation of corrected QT interval (QTc) > 480 msecs
- History of any one or more cardiovascular conditions within the past 6 months prior to randomization
- Poorly controlled hypertension
- History of cerebrovascular accident (including transient ischemic attacks), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months prior to randomization
- Major surgery (including interval debulking) or trauma within 28 days, or minor surgical procedures within 7 days, prior to randomization, or has any non-healing wound, fracture, or ulcer.
- Evidence of active bleeding or bleeding diathesis.
- Hemoptysis within 6 weeks prior to randomization.
- Endobronchial metastases.
- Serious and/or unstable pre-existing medical (e.g., uncontrolled infection), psychiatric, or other condition that could interfere with subject’s safety, provision of informed consent, or compliance to study procedures.
- Investigational or anti-VEGF anticancer therapy prior to study randomization.
- Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to pazopanib.
- Prior or concurrent invasive malignancies that currently or within the last 5 years show/ed activity of disease (except ovarian, fallopian tube, or peritoneal cancer, or concurrent endometrial cancer FIGO stages IA/B)
Trial location(s)
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
No longer a GSK study
Actual primary completion date
2012-12-10
Actual study completion date
2014-10-01
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website